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Variants of the SCN1A gene encoding the neuronal voltage-gated sodium channel NaV1.1
cause over 85% of all cases of Dravet syndrome, a severe and often pharmacoresistent
epileptic encephalopathy with mostly infantile onset. But with the increased availability of
genetic testing for patients with epilepsy, variants in SCN1A have now also been described
in a range of other epilepsy phenotypes. The vast majority of these epilepsy-associated
variants are de novo, and most are either nonsense variants that truncate the channel or
missense variants that are presumed to cause loss of channel function. However,
biophysical analysis has revealed a significant subset of missense mutations that result
in increased excitability, further complicating approaches to precision pharmacotherapy
for patients with SCN1A variants and epilepsy. We describe clinical and biophysical data of
a familial SCN1A variant encoding the NaV1.1 L1624Q mutant. This substitution is located
on the extracellular linker between S3 and S4 of Domain IV of NaV1.1 and is a rare case of a
familial SCN1A variant causing an autosomal dominant frontal lobe epilepsy. We
expressed wild-type (WT) and L1642Q channels in CHO cells. Using patch-clamp to
characterize channel properties at several temperatures, we show that the L1624Q variant
increases persistent current, accelerates fast inactivation onset and decreases current
density. While SCN1A-associated epilepsy is typically considered a loss-of-function
disease, our results put L1624Q into a growing set of mixed gain and loss-of-function
variants in SCN1A responsible for epilepsy.
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INTRODUCTION
SCN1A encodes the alpha subunit of the neuronal voltage gated sodium channel NaV1.1 and variants
of this gene are known to cause a variety of epilepsy phenotypes in humans. The alpha subunit is the
primary component of the sodium channel and is sufficient to conduct current although it is typically
paired with auxiliary beta subunits in vivo (Marban et al., 1998). Voltage gated sodium channels are
comprised of four homologous domains (DI-DIV) (Noda et al., 1984). Each domain is made up of six
transmembrane segments (S1–S6); S1–S4 make up the voltage sensing region, while S5 and S6 form
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the channel pore. Upon depolarization, the movement of the
positively charged S4 segment toward the extracellular surface
causes a conformational change that opens the pore, resulting in
an influx of sodium (Kontis et al., 1997; Chanda and Bezanilla,
2002; Peters and Ruben, 2014). Within a few milliseconds, the
intracellular loop connecting DIII and DIV (illustrated as h in
Figure 1), moves to block the channel pore and prevent further
sodium influx in a process termed fast inactivation (Marban et al.,
1998).
The association between SCN1A and epilepsy is best
documented for Dravet syndrome, a severe developmental and
epileptic encephalopathy (Dravet, 1978; Covanis, 2012; McTague
et al., 2016), with up to 85% of patients with Dravet syndrome
carrying a pathogenic variant in SCN1A (Rosander and Hallböök,
2015; Cooper et al., 2016). Dravet syndrome presents with a
difficult to treat (Chiron, 2011) epilepsy with multiple seizure
types, including hemiclonic, myoclonic and tonic-clonic seizures
in previously healthy infants within the first year of life, and is
typically followed by developmental delays (Yakoub et al., 1992;
Engel, 2001; Wolff et al., 2006; Dravet, 2011; Rosander and
Hallböök, 2015). In many cases, seizures are triggered by
elevated body temperature, which can be the result of a fever,
exercise, or taking a hot bath (Dravet, 2011).
However, SCN1A gene variants are also a recognized cause for
epilepsies and neurodevelopmental disorders outside the Dravet
syndrome spectrum—ranging from milder phenotypes such as
generalized epilepsy with febrile seizures plus (Escayg et al.,
2000), to other epilepsy syndromes such as myoclonic astatic
epilepsy, epilepsy of infancy with migrating focal seizures, or even
to recently described more severe early onset epileptic
encephalopathies with neurodegeneration and dyskinesia
(Sadleir et al., 2017; Beck et al., 2019; Gorman et al., 2021).
With increased genetic testing, SCN1A variants have been
described in patients with focal epilepsies (Vezyroglou et al.,
2020)—both in patients that were candidates for epilepsy surgery,
and those with self-limiting focal epilepsies of childhood. These
patients are part of a minority of cases of focal epilepsy for which
single gene causes have been identified. Other well-characterized
focal epilepsies with single gene causes include familial focal
epilepsy with variable foci caused by DEPDC5 variants (Dibbens
et al., 2013), childhood epilepsy with centro-temporal spikes
caused by GRIN2A variants (Lemke et al., 2013), and
autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE) associated with CHRNA4, CHRNB2, CHRNA2,
KCNT1, DEPDC5, or CRH (Kurahashi and Hirose, 2002).
In a meta-analysis of genome-wide association studies
(GWAS) across unselected epilepsies, SCN1A is one of only
few genes with a significant association with epilepsy.
Furthermore, other neurological and neurodevelopmental
disorders, such as hemiplegic migraine and autism spectrum
disorders, have now been described in the context of SCN1A
variants (Scheffer and Nabbout, 2019). Taken together, these
insights suggest much greater relevance of variants in SCN1A in a
range of neurodevelopmental disorders extending beyond Dravet
syndrome.
Over 1,200 SCN1A distinct variants have been associated with
epilepsy (Meng et al., 2015; Gonsales et al., 2019). Although
traditionally considered a loss-of-function disease, biophysical
analysis has revealed a wide range of presentations, with some
variants resulting in an increase in channel function, others a
decrease, and some a mixture of loss- and gain-of-function
(Sugawara et al., 2003; Rhodes et al., 2004; Ohmori et al.,
2006; Escayg and Goldin, 2010; Liao et al., 2010; Meng et al.,
2015; Peters et al., 2016; Berecki et al., 2019). This heterogeneity
makes SCN1A epilepsies extremely challenging to treat, as a
medication that improves seizures in one patient may
exacerbate them in another. For example, both lamotrigine
and carbamazepine have been found to worsen seizures in
Dravet Syndrome (Wakai et al., 1996; Guerrini et al., 1998; Shi
et al., 2016) but there has been contrasting evidence suggesting
that they have been an effective therapy for a subset of patients
(Dalic et al., 2015; Snoeijen-Schouwenaars et al., 2015). This
highlights the importance of individualized therapy for patients
with SCN1A related epilepsies, and the need for a better
FIGURE 1 | Voltage-Gated Sodium Channel Structure. Structural depiction of a mammalian voltage-gated sodium channel, modified from (Peters et al., 2016). The
location of the L1624Q variant is shown with a red arrow. Other emphasized regions include the S4 voltage-sensing segments (yellow), the pore-forming regions (blue),
and the intracellular loop involved in fast inactivation (h).
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understanding of the range of epilepsy-causing variants.
Unfortunately, to date the ability to consistently predict links
between genotype, channel function, and phenotype remains
elusive (Brunklaus and Lal, 2020).
This paper presents both clinical and biophysical data for the
SCN1A variant c.4871T > G; p. L1624Q. In contrast to the more
typical de novo variants, L1624Q was found across a two-
generation pedigree. Unusually, affected members showed
nocturnal hypermotor seizures that were confirmed to be of
frontal lobe origin by video-EEG-monitoring in the index case,
diagnostic of autosomal dominant nocturnal frontal lobe epilepsy
without a family history of febrile seizures. This variant is located
on the extracellular linker between S3 and S4 of Domain IV of
NaV1.1 (Figure 1). Using patch-clamp to characterize channel
properties, we show that the L1624Q variant causes an increase in
persistent current, accelerates fast inactivation onset, and
decreases current density. Experiments were conducted at both
22°C and 37°C to provide a measure of temperature sensitivity
with data that allows comparison to previous studies. While most
SCN1A-related epilepsies are typically considered a loss-of-
function disease, our results put L1624Q into a growing set of
mixed gain and loss-of-function variants in SCN1A responsible
for early childhood epilepsy.
METHODS
Patient Selection
Patients who have tested positive for missense variants in
SCN1A on clinical genetic testing at the tertiary epilepsy
service at King’s College Hospital/Evelina London
Children’s Hospital, London were collated in a research
database. There, an anonymized, limited set of clinical
information is being captured, including syndromic
electroclinical diagnoses, and limited information on
family history. Ethical approval for the use of single gene
sequencing data and anonymized clinical information has
been given by the UK Health Research Authority (IRAS
229772).
Based on this database, we identified the patient carrying the
L1624Q variant based on a syndromic diagnosis of autosomal
nocturnal frontal lobe epilepsy, classically characterized by
recurrent, nocturnal focal seizures of frontal lobe origin with a
positive family history of similar seizures in first degree relatives
suggesting an autosomal inheritance.
Clinical Features
The identified patient was born by elective caesarean at term and
there were no significant immediate problems. Her mother was
on lamotrigine, sodium valproate, and carbamazepine during the
pregnancy. There were some early developmental concerns with
mild motor delay (walking at 18 months) and she was later
identified as being hypermobile. She had delayed speech
milestones, not putting sentences together until age three and
half years. A comprehensive assessment at age 7.9 years
demonstrated a marked discrepancy between verbal and non-
verbal scores with non-verbal reasoning, visuospatial skills, and
processing in the upper end of the ability range [PIQ 131 (98%)].
Verbal abilities and working memory were markedly lower
especially for comprehension tasks with some scores in the
impaired range so that a meaningful overall verbal IQ score
could not be expressed. Further language assessments
demonstrated that processing and producing language was
effortful and her profile was consistent with a developmental
language disorder. There was no evidence for an additional
autism spectrum disorder. Of note at the time of this
assessment, she was on monotherapy with low dose
lamotrigine so it is unlikely that there were adverse effects of
medication contributing to this profile.
The child’s habitual seizures had begun around a year of age
with recurrent brief nocturnal motor seizures with the
appearance on home video recordings of asymmetric
predominantly tonic motor seizures. On occasions as she got
older, she reported daytime visual phenomena with visual
hallucinations then numbness of either arm and then
headache suggestive of a migrainous etiology, though she also
reported from time to time that the same visual features would
occur prior to her motor seizures at night. Treatment with
valproate was unsuccessful, levetiracetam made behavior worse
and exacerbated the visual hallucinations, whereas lamotrigine in
modest dose appeared most helpful. Higher dose appeared to
make the situation worse. The addition of clobazam at night was
helpful. Illness was a clear trigger for seizures, but most occurred
spontaneously.
Her mother reported a history of focal seizures in several
generations with her own epilepsy continuing to be difficult
to control, but with lamotrigine felt to be the most helpful
medication. She was cognitively able but there was an
impression again of problems processing and expressing
language, which appeared more than those expected as
English was being spoken as a second language. She had
not been formally tested. The child’s older sister had a history
of epilepsy as did her older brother in his case beginning
around age 6 again manifesting as recurrent nocturnal
seizures. Treatment with valproate was helpful initially but
seizures recurred when this was withdrawn and then did not
respond to this, so levetiracetam and then lamotrigine was
substituted. He also developed seizures with an initial visual
aura, in his case with black and white dots and then visual
obscuration evolving into predominantly asymmetric tonic
seizures. He also reported that daytime seizures could be
triggered by patterns. The addition of low dose clobazam at
night was also helpful for him. He had additional co-
morbidities with some educational difficulties, dyspraxia
and autism but was in mainstream schooling throughout.
Gene profiling was performed using next generation
sequencing on blood samples. No variants had been identified
in the genes typically associated with autosomal dominant
nocturnal frontal lobe epilepsy (CHRNA4, CHRNB2,
CHRNA2 < KCNT1, DEPDC5, CRH).
Mutagenesis and Bacterial Transformation
Wildtype SCN1A DNA in a PCDM8 vector was used for
mutagenesis, and has been described in a previous paper
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(Peters et al., 2016). The L1624Q variant was generated using a
QuikChange Lightening Site Directed Mutagenesis Kit (Agilent
Technologies) with the following primers:
Forward: 5′ cac gaa ata ctt ttc tat ctg ctc ggc aag aaa cat acc 3′
Reverse: 5′ ggt atg ttt ctt gcc gag cag ata gaa aag tat ttc gtg 3′
DNA was transformed into TOP10/P3 Escherichia coli
bacteria (Invitrogen) and grown at 30°C. The entire length of
the sodium channel was sequenced to confirm that no
spontaneous mutations had occurred.
Cell Culture
CHOk1 cells (Sigma-Alrich) were grown in Ham’s F-12 nutrient
mixture supplemented with 10% FBS (Gibco) at 37°C. Using
Polyfect (Qiagen), cells were transfected with 1 μg of SCN1A
(wildtype or mutant), 1 μg of eGFP, and 0.5 μg of the β1 subunit.
Cells were plated on sterile glass coverslips approximately 24 h
after transfection, and experiments were performed 24–48 h later.
Patch Clamp Experiments
Whole cell patch clamp experiments were performed at 22°C and
37°C with an EPC9 patch-clamp amplifier (HEKA Elektronik)
and Patchmaster software (Heka Electronic). Temperature was
maintained with a TC-10 Temperature controller (Dagan). Glass
pipettes were pulled with a P-1000 puller (Sutter Instruments),
dipped in wax, and polished to a resistance of 1.0–1.5 MΩ.
Intracellular solution contained 130 mM CsF, 10 mM NaCl,
10 mM EGTA, and 10 mM HEPES. Extracellular solution
contained 140 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM
MgCl2, and 10 mM HEPES. Both solutions were titrated to a
pH 7.4 with CsOH.
Protocols
To determine the voltage-dependence of channel activation,
membrane potential was depolarized to potentials between
−100 mV and +70 mV for 10 ms from a holding potential of
−130 mV. Conductance was determined by dividing peak current
by the observed reversal potential subtracted from membrane
potential. Normalized conductance was plotted against voltage
and fit by a Boltzmann equation. The time constant of fast
inactivation onset at voltages between −30 mV and +20 mV
was determined by fitting the decay of the current with a
single exponential equation. Current density was calculated
with current at 0 mV.
To measure the voltage-dependence of channel fast
inactivation, the membrane was held at potentials ranging
from −130 mV to +10 mV for 200 ms, followed by a 19 ms
test pulse at 0 mV. Steady-state fast inactivation was measured
as the proportion of current remaining in the 0 mV test pulse. The
normalized current was plotted against voltage and fit by a single
Boltzmann equation.
The rate of inactivation recovery was determined by holding
the membrane potential at 0 mV for 200 ms followed by a
−90 mV recovery pulse for increasing amounts of time. The
time of fast inactivation recovery was measured as the
proportion of current after the −90 mV recovery pulse. The
normalized current was plotted versus recovery time and fit
with a double exponential equation.
The fraction of non-inactivating current was measured
during a 50 ms pulse from −130 to 0 mV. The percentage of
persistent current was determined by dividing the current
amplitude measured at the end of the 50 ms depolarizing
pulse by the peak current. The current amplitude measured
between 25 and 30 ms was also divided by the peak current to
confirm that the persistent current had stabilized and reached
steady-state.
Statistical Analysis
Statistical analysis was performed with JMP software (SAS
Institute) using a multi-factor analysis of variance. To test
whether the L1624Q variant and wildtype channels have
differential temperature sensitivity, the interaction between
temperature and mutant was used as a predictor variable in
the model. If no differential temperature sensitivity was found,
temperature and mutant effects were evaluated independently.
Fast inactivation onset time constants ranging from −30 mV to
+20 mV were log transformed prior to analysis such that values
were normally distributed. Statistical significance was defined as
p < 0.05.
Neuronal Action Potential Modelling
To simulate how L1624Q-dependent perturbations on
channel gating alter cortical neuron firing, we modified
prior models of pyramidal neuron firing (Traub et al.,
1991; Destexhe et al., 1994). The methodology is described
in prior publications (Peters et al., 2016; Gorman et al., 2021)
and codes to run cortical neuron simulations in Python are
freely available online (https://github.com/roschkoenig/
SodMod). The increased rate of inactivation onset in the
L1624Q variant at 37°C was implemented by multiplying the
rate of inactivation onset by 1.485, reflecting the average
increase in inactivation rates measured between −30 and
+20 mV at 37°C. Because persistent sodium currents were
not included in the original cortical neuron model, a non-
inactivating (lacking the “h” gate) component of the fast
sodium current was implemented with activation and
deactivation rates 1,000 times those of the fast sodium
current. The maximal conductance of the non-inactivating
current was set at 10% of the fast component multiplied by
the measured fraction of inactivating current at 37°C (1.8% in
WT and 4.6% in L1624Q; see https://github.com/
roschkoenig/SodMod).
We implemented single-compartment neuron models that
were stimulated with three different regimes. Injections of
1–100 pA for 1 s were used to measure the effects of the
L1624Q variant on the rates of action potential firing at
steady-state (Figures 5A,B). To measure the effects of L1624Q
on persistent action potential firing, cells were injected with 10 pA
of current for 50 ms after which the stimulus was removed
(Figure 5C). Finally, to measure membrane dynamics across a
range of injected currents, action potential firing was measured
during a slowly increasing ramp of current injection between
∼0.002 and 400 pA (Figure 6). Ramps were delivered following a
period of inactivity with no current injection or following a 10 ms
pre-stimulus of 10 pA to induce neuronal firing.
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RESULTS
L1624Q Decreases Current Density at 37°C,
but Does not Shift the Voltage-Dependence
of Activation
Sample macroscopic sodium currents from WT (black) and
L1624Q (red) channels at 22°C and 37°C are shown in Figures
2A–D. At 22°C, there are no significant differences in the
current density between mutant and WT channels, indicating
functional channel expression with the L1624Q variant (p 
0.5725; Figure 2E); however, current density is significantly
reduced in L1624Q channels at 37°C (WT  72.82 pA/pF, LQ
 45.42 pA/pF; p  0.0021; Figure 2E). There is no significant
mutant or temperature-dependent effect on the midpoint
(V1/2) of the conductance-voltage relationship (p  0.0791
and p  0.4971 respectively). These results indicate that at
physiological temperatures the L1624Q variant causes a loss-
of-function by reducing peak current amplitudes, but this
effect is not due to changes in channel activation.
L1624QSpeeds the Rate of Fast Inactivation
Onset
Steady state fast inactivation curves at 22°C and 37°C are
compared in Figures 3A,B. There is a significant right shift in
the midpoint of steady-state fast inactivation with increased
temperature (p  0.0123), but it does not differ between WT
and variant (p  0.6998). The rates of fast inactivation onset
in the L1624Q variant are significantly more sensitive to
increases in temperature compared to WT channels (p 
0.0089). While there are no differences in the rate of fast
inactivation at 22°C in L1624Q compared to WT (p ≥ 0.2680;
Figure 2C), the L1624Q variant increases the rate of fast
inactivation onset at 37°C between −20 and +20 mV (p ≤
0.0116; Figure 3D). The rate of recovery from fast
inactivation at −90 mV is not significantly difference
between L1624Q and wildtype (p  0.8490).
L1624Q Increases Persistent Current
The fraction of non-inactivating (persistent) current was
measured at the end of 50 ms depolarizations at 22°C and
37°C (Figures 4A,B). Persistent current is significantly higher
in L1624Q channels compared to wildtype at both 22°C
(INAPLQ  3.20%, INAPWT  0.95%; p  0.0039) and 37°C
(Figure 4C; INAPLQ  4.58%, INAPWT  2.27%; p  0.0032).
In contrast to the loss-of-function in peak current amplitude, this
indicates that the L1624Q variant causes a gain-of-function in the
fraction of non-inactivating current.
Neuronal Simulations
To investigate the effects of the L1624Q variant on cortical
neuron excitability we implemented a single-compartment
pyramidal neuron simulation based on previously published
models (Traub et al., 1991; Destexhe et al., 1994; Peters et al.,
2016). Sodium currents in the simulated L1624Q neurons were
parameterized to reflect the increased rate of fast inactivation
onset and the increased fraction of non-inactivating sodium
FIGURE 2 | L1624Q reduces peak current density. (A–D): Representative macroscopic inward sodium currents. WT (black) and L1624Q (red) traces are shown at
22°C (A,B) and 37°C (C,D). (E): Bar chart comparing mean sodium current density at 0 mV in WT and L1624Q cells at 22°C (nWT  28, nLQ  28) and 37°C (nWT  28,
nLQ  41). (F,G): Normalized conductance curves for WT (black) and L1624Q (red) channels are shown at 22°C ((F), nWT  7, nLQ  6) and 37°C ((G), nWT  10, nLQ  8).
Insets show the voltage protocol. All midpoint measurements are means and error bars represent standard error of the mean.
Frontiers in Pharmacology | www.frontiersin.org December 2021 | Volume 12 | Article 7881925
Jones et al. L1624Q Causes Mixed Channel Dysfunction
FIGURE 3 | L1624Q speeds the rate of fast inactivation onset. (A,B): Voltage-dependence of steady-state fast inactivation inWT (black) and L1624Q (red) channels
at 22°C (A, nWT  9, nLQ  9) and 37°C ((B), nWT  8, nLQ  8). The inset shows the voltage-protocol used to measure steady-state inactivation. (C,D): Fast inactivation
onset time constants plotted against membrane potential at 22°C (C, nWT  5, nLQ  8) and 37°C ((D), nWT  7, nLQ  8). All midpoint measurements are mean and error
bars represent standard error of the mean.
FIGURE 4 | L1624Q increases persistent current. (A,B): Representative normalized current traces fromwildtype (black) and L1624Q (red) channels at 22°C (A) and
37°C (B). Insets: Zoomed in view of the non-inactivating currents. (C): Bar chart comparing the fraction of persistent current in WT (black) and L1624Q (red) channels at
22°C (nWT  5, nLQ  4) and 37°C (nWT  4, nLQ  5). All midpoint measurements are mean and error bars represent standard error of the mean.
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current. The increased rate of inactivation in turn decreases
peak currents in the L1624Q model by approximately 25%
(Figure 5B inset). This decrease is within the 95% confidence
interval for the experimental decrease in peak current density
in the L1624Q mutant (6.61−68.64%). In response to
prolonged stimulations at set input currents up to 40 pA,
the L1624Q expressing neurons fired at lower current
injections (Figure 5A) and at slightly faster rates
(Figure 5B) than WT neurons. In response to a short
stimulus injection, the L1624Q simulations display
persistent action potential firing that continues after the
stimulus is removed (Figure 5C). Persistent firing did not
terminate within the 1s simulation time. Persistent firing in
the L1624Q variant is seen during a slowly increasing
stimulus current ramp following a period of action
potential firing (Figure 6). Interestingly, the L1624Q
simulations enter depolarization block at lower stimulus
currents than the WT simulations during stimulus ramps
from rest or following action potential firing (Figure 6).
To further investigate the effects of increased persistent
currents and faster rates of inactivation onset in L1624Q, we
also modelled these effects separately. These models show that the
increased persistent currents in L1624Q are primarily responsible
for lower firing thresholds (Supplementary Figure S1A) and
persistent AP firing (Supplementary Figure S1B). In addition,
reduced current due to faster inactivation allows for slightly faster
firing rates and is also partially responsible for the increased
depolarization block in L1624Q (Supplementary Figure S1C).
Overall, these simulations suggest that the mixed gain- and loss-
of-function in the L1624Q variant leads to hyperexcitability at
lower stimulus inputs and diminished excitability during larger
stimuli.
DISCUSSION
Despite the strong association between variants of the SCN1A
gene and Dravet syndrome, there is considerable heterogeneity in
FIGURE 5 | L1624Q increases neuronal excitability at lower input stimuli. (A): Simulated action potential firing inWT (black) and L1624Q (red) expressing neurons at
37°C in response to stimulus currents (bottom) of 1 pA (second from bottom), 1.5 pA (middle), 2 pA (second from top), or 5 pA (top). (B): Simulated action potential
firing rates of WT and L1624Q expressing neurons in response to stimuli between 1 and 100 pA. (B) inset: Simulated WT (black) and L1624Q (red) sodium currents in
response to a test pulse to 0 mV from a holding potential of −120 mV. (C): Simulated action potential firing of WT (black) and L1624Q (red) expressing neurons in
response to a 10 pA stimulus for 50 ms followed by zero stimulus (bottom).
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the phenotypes of SCN1A associated epilepsies (Sugawara et al.,
2003; Ohmori et al., 2006; Escayg and Goldin, 2010; Liao et al.,
2010; Meng et al., 2015; Peters et al., 2016). In fact, even in
genome-wide analyses of common epilepsies, SCN1A is identified
as a key risk gene (Anney et al., 2014) suggesting that the
phenotypes associated with SCN1A variants extend far beyond
the patients with more severe childhood onset epilepsies in whom
a clinical diagnosis of SCN1A variants is now made on routine
clinical testing. We currently lack the ability to make in silico
predictions about channel function from genetic data (Brunklaus
and Lal, 2020), limiting the current use of genetic insights in
guiding treatment and prognosis for the heterogeneous SCN1A-
related epilepsies. Understanding the functional effects of unique
mutants, particularly when associated with unusual phenotypes,
is an essential next step for understanding genotype-phenotype
relationships in SCN1A-associated epilepsies. Here we show that
the familial L1624Q variant is associated with increased persistent
current as well as accelerated fast inactivation onset and
decreased current density in response to increased
temperature. Simulations of cortical neuron firing predict that
this mixture of loss- and gain-of-function effects will cause both
hyperexcitability, in the form of persistent firing, as well as
increased entry into depolarization block. Although most
SCN1A-associated epilepsies are considered a loss-of-function
disease, our results put L1624Q into a growing set of mixed gain
and loss-of-function variants in SCN1A responsible for an
increasing set of epilepsy phenotypes (Meng et al., 2015).
Familial Variants in Epilepsy
Even though epilepsy is highly heritable, only for a minority
of patients can a single gene diagnosis currently be
established. The yield of genetic diagnoses is highest in the
early epileptic encephalopathies, for epilepsies associated
with certain comorbidities, and for certain epilepsy
syndromes, such as familial focal epilepsies (Mullen et al.,
2013; McTague et al., 2016; Stefanski et al., 2021). However,
despite the high heritability in the epilepsies generally, few
patients with a familial epilepsy are diagnosed with a single
causative gene mutation. In a population based Scottish
national cohort study of 333 patients with epilepsy
presenting with seizure onset before the age of 36 months,
15 of 80 single gene diagnoses made were in familial
epilepsies with variants inherited from an affected parent
(Symonds et al., 2019).
Among the familial focal epilepsies, autosomal dominant
nocturnal frontal lobe epilepsy (or autosomal dominant sleep-
related hypermotor epilepsy) was one of the first epilepsy
syndromes in which causative single gene mutations could be
identified in patients. Yet collectively the known genes only
explain approximately 10% of cases. Similarly, the yield of
genetic testing across familial focal epilepsies remains below
∼12% even with panel and genomic testing approaches
(Tinuper et al., 2016; Oates et al., 2018).
For SCN1A, familial cases have initially helped establish an
association with epilepsy in the context of generalized epilepsy
with febrile seizures plus (GEFS+) (Wallace et al., 2001).
However, most variants are now detected in sporadic cases of
Dravet syndrome as de novo variants. Only about 10% of SCN1A
variants are familial, and these are typically associated with
milder phenotypes (Meng et al., 2015). The case presented
here represents an extension of the SCN1A-associated epilepsy
phenotypes with the clinical features of an epilepsy syndrome
classically associated with different genetic causes.
Persistent Current
Perhaps the most striking effect of the L1624Qmutant on channel
activity was the large increase in persistent current passed by the
channels. Despite its relatively small amplitude, persistent current
can have profound impacts on sodium channel function, such as
enhancing repetitive firing, heightening depolarization in the sub-
and near-threshold voltage range, and reducing the threshold for
action potential firing (Rhodes et al., 2004; Stafstrom, 2007; Deng
and Klyachko, 2016). This abnormal neuronal activity often
results in epilepsy syndromes. For example, the SCN1A variant
P1632S, also located on the extracellular linker between S3 and S4
of Domain IV, exhibits a similar pattern of increased persistent
current and an accelerated fast inactivation fast time constant τ1
leading to childhood epilepsy (Rhodes et al., 2005). Indeed, our
simulations predict that persistent currents in the L1624Q variant
lead to continued action potential firing even after a stimulating
current is removed. Interestingly, lamotrigine, a sodium channel
blocker that is effective in reducing persistent current at clinically
appropriate doses (Stafstrom, 2007), was reported to be effective
in the L1624Q patients, despite being notorious for aggravating
SCN1A related seizures (Guerrini et al., 1998; Chiron, 2011;
FIGURE 6 | L1624Q leads to depolarization block at lower input stimuli.
Simulated action potential firing in WT (black) and L1624Q (red) expressing
neurons at 37°C in response to a slowly increasing stimulus current (bottom).
Simulations are conducted following a period of rest with zero stimulus
(top) or following a 10 ms pre-stimulus of 10 pA to induce AP firing (bottom).
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Anderson et al., 2017). This effect highlights the variability in
response to anti-convulsant drugs and the considerable
heterogeneity between patients with SCN1A related epilepsies.
Mixed-Function Variants in Epilepsy
The L1624Q variant falls into a growing class of mixed loss- and
gain-of-function variants in NaV1.1 (Ohmori et al., 2002; Claes
et al., 2003; Rhodes et al., 2004; Rhodes et al., 2005; Volkers et al.,
2011; Peters et al., 2016; Sadleir et al., 2017; Berecki et al., 2019;
Brunklaus and Lal, 2020; Gorman et al., 2021). These variants are
characterized by multiple defects that cause opposing effects on
channel activation and inactivation. In many cases this takes the
form similar to what we report here where increases in persistent
sodium current occur along with a decrease in the peak sodium
current (Escayg et al., 2001; Lossin et al., 2002; Ohmori et al.,
2002; Fujiwara et al., 2003; Rhodes et al., 2004; Spampanato et al.,
2004; Rhodes et al., 2005; Volkers et al., 2011). As discussed
above, increases in persistent current can produce spontaneous
activity and burst firing. In contrast, other variants that shift the
activation and inactivation voltage dependences can alter the
threshold for AP firing or alter depolarization block at higher
inputs (Peters et al., 2016; Berecki et al., 2019). The L1624Q
variant studied here shows a mixture of increased persistent
currents and decreased peak current density. It is likely that
the decreased peak current at higher temperatures is due to the
rapid fast inactivation onset in this variant that may lead to
significant inactivation before channels are fully activated as was
shown in other sodium channel isoforms (Peters et al., 2017;
Peters et al., 2020).
The mixture of loss- and gain-of-function in other voltage-
gated sodium channel isoforms is known to cause overlapping
syndromes with characteristics of multiple disease states; these
include mixed Brugada and long QT syndrome type 3 variants in
NaV1.5 (Bezzina et al., 1999; Abdelsayed et al., 2015) as well as
mixed periodic paralysis and myotonia variants in NaV1.4 (Webb
and Cannon, 2008; Ghovanloo et al., 2018). Thus far, the growing
list of mixed variants in NaV1.1 have been part of the epileptic
spectrum, ranging from less severe generalized epilepsy with
febrile seizures (GEFS+) to severe infantile epileptic
encephalopathies (Escayg et al., 2001; Lossin et al., 2002;
Peters et al., 2016; Volkers et al., 2017; Brunklaus and Lal,
2020). The mixed variant T226M has been associated with a
more severe early onset, atrophy of the brain, and dyskinesia due
to a lack of depolarization block (Sadleir et al., 2017; Berecki et al.,
2019). We recently reported a case of a large inward persistent
current causing drug resistant and fatal epilepsy with atrophy and
a dyskinetic disorder (Gorman et al., 2021). Drug resistance is not
uncommon in epilepsy associated with SCN1A variants, and has
also been reported in many of the mixed-function variants
discussed above (Claes et al., 2003; Fujiwara et al., 2003;
Rhodes et al., 2004; Sadleir et al., 2017). Some of these
patients have benefited from anti-epileptic drugs such as
lamotrigine (Volkers et al., 2011), sodium valproate (Volkers
et al., 2011; Peters et al., 2016) and levetiracetam (Volkers et al.,
2011), but there is no evidence that any of these drugs are a
panacea for mixed-function variants in SCN1A. The current case
demonstrates that specific dysfunction in NaV1.1 beyond simple
loss of function may be associated with phenotypes not classically
associated with mutations in SCN1A. These expansions of the
phenotypic spectrum of SCN1Amutations further complicate the
already tenuous relationships between genotype and phenotype
(Brunklaus and Lal, 2020). Whether additional data will delineate
other loss-of-function and gain-of-function variants into clear
phenotypes remains to be tested.
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